Hospital Universitario Lucus Augusti
Lugo, 27003, Spain
NCT Number: NCT06824584
The goal of this observational study is to assess the physical fitness and the influence of possible factors (disease symptomatology, cognitive status, patient functioning and degree of perceived quality of life) on patients diagnosed with schizophrenia and schizoaffective disorder older than 18 years in an outpatient setting. The main question it aims to answer is:
Do the symptoms of the illness influence the level of physical fitness of patients?
Participants will complete a series of questionnaires assessing their cognitive status, perceived quality of life and disease severity, and physical activity assessments to measure their cardiovascular endurance and muscular power.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
Lugo, 27003, Spain
A mixed-methods research design will be carried out. Two different study designs will be used:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At baseline and after 3 months follow-up.
requires the patient to walk/run a 10m course (delimited 0.5m from each end by a cone) at a speed that increases 0.6 km/h every minute. The start of the race is marked by a triple beep and each lap is indicated by a single beep. At the conclusion of each level, patients were instructed to increase their speed slightly and reminded that they were free to accelerate at any time during the test. The trial concluded under the following conditions: (1) the participant became too breathless to sustain the prescribed pace, (2) the participant deviated more than 0.5 m from the cone upon the beep, (3) the participant attained a heart rate exceeding 85% of their age-predicted maximum, or (4) in case the patient reported symptoms such as chest pain, angina, dizziness, mental confusion, or severe muscular exhaustion. With the meters performed in the test, we will estimate the maximum oxygen consumption (VO2max), using the formula proposed by Tous-Espelosin et al. in 2021.
Time frame: At baseline and after 3 months follow-up.
Participants will be instructed to sit in an armless chair of standard height (48 cm) with a hard seat, placed firmly against a wall. They will be required to cross their arms over their chest and keep their feet flat on the floor, wearing stable footwear throughout the test. Participants will be asked to stand up and sit down, landing firmly on the seat, five times as quickly as possible on the command "go". If the patient performs the test in 30 seconds or more, this time will be noted, and the test score will be recorded as 30 seconds. Using the Powerfrail app, the examiner will record the test performance on video to time the five repetitions, in addition to calculating the muscle power in W/kg.
Time frame: At baseline and after 3 months follow-up.
will be measured with a dynamometer (Takei model) following a standardized methodology developed by the University of Southampton in 2011, based on the recommendations of the American Society of Hand Therapists (ASHT). The patient will be seated in a chair with legs, backrest and arms fixed, forearms on the arms of the chair and wrist in neutral position with the thumb up. The patient will perform a measurement first with the right hand, then with the left hand and then repeat the procedure 2 more times. The best of the six measurements will be used for statistical analysis.
Universidade da Coruña
Other
Acronym: COFESQ
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07408934
Mental Disorders, Psychotic Disorders
Ottawa, Ontario, Canada
View Trial DetailsNCT07086040
Mental Disorders, Psychotic Disorders
Taipei, Taiwan
View Trial DetailsNCT07005245
Bipolar Disorder, Bipolar Disorder (BD)
Beijing, Haidian District, China
View Trial DetailsNCT00292409
Mental Disorders, Psychotic Disorders
View Trial Details